US Centres for Medicare and Medicaid Services (CMS) has said it will pay for any COVID-19 vaccine that is authorised or approved by the US Food and Drug Administration to allow for "broad vaccine access and coverage for all Americans.", CNN reported on Thursday.
Also, the agency announced it will help cover a larger portion of the cost of new COVID-19 treatments that may be coming down the pipeline for Medicare recipients.
CMS administrator, Seema Verma, was quoted as saying during a briefing on 28 October: "There are several vaccines in Phase 3 trials, production and distribution plans are well underway, and CMS is doing its part by laying the essential groundwork for coverage and payment when a vaccine does arise. It'll be widely available and accessible to seniors and every American."
She added that while the US federal government is paying for the vaccine, insurers including Medicare, Medicaid and private plans must cover the cost of administering it.
Precision Biosciences initiates patient enrollment in PBGENE-DMD clinical study
Immunome submits FDA application for varegacestat following strong Phase 3 results
HUTCHMED secures priority review for sovleplenib NDA in China
Chiesi Group to acquire KalVista Pharmaceuticals for USD1.9bn in rare disease expansion strategy
Circio partners with USC to advance non-viral RNA delivery technologies
Cirius Therapeutics introduces gestational diabetes initiative
Vanda Pharmaceuticals reports publication of imsidolimab phase III findings in NEJM Evidence
GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation